Oct 10 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N), opens new tab said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to ...

Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...

FILE PHOTO: A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File Photo (Reuters) -Drugmaker Bristol Myers Squibb said on ...

The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a ...

Acquisition includes OTX-201, an investigational next-generation CAR T-cell therapy designed to reprogram cells in vivo with potential best-in-class profile for autoimmune diseases Transaction further ...

Eight years after Novartis AG gained U.S. FDA approval of the first CAR T therapy, Kymriah (tisagenlecleucel), for B-cell acute lymphoblastic leukemia, developers are advancing prospects that could ...

IoCDB Share project repository, a CTI platform that collects data from VirusTotal, AlienVault OTX, PolySwarm and AbuseIPDB APIs for hashes, domains and IPs. AegisFlow is a threat-aware CI/CD pipeline ...

College Football CFB - Texas Longhorns vs. Ohio State Buckeyes - 08/30/2025 Ohio State Buckeyes Texas Longhorns BIG NOON KICKOFF ...

A smartphone-based digital therapeutic application designed to deliver suicide-focused cognitive-behavioral therapy (CBT) was associated with a sustained reduction in suicidal ideation through 24 ...